The high price tag for a new Alzheimer’s drug has fueled the ongoing drug price debate. But will patients really pay sticker price? (Spoiler alert: No!).
Co-host Dr. Bob Goldberg explains the research/value assessment of the drug, while Host Terry Wilcox discusses the growing barriers to access the drug even as health networks refuse to offer it and the Institute for Clinical and Economic Review (ICER) decides to ignore its benefits.
Hear from UsAgainstAlzheimer’s COO Russ Paulsen about this breakthrough and what it means for the community, particularly minority populations. Also, against a backdrop of debates over high health care and prescription drug costs, Dr. Mark Fendrick and Dr. Jon Schommer take time to explain the problems they see affecting patients.
Dr. Robert Goldberg, “Dr. Bob,” Co-Founder and Vice President of the Center for Medicine in the Public Interest
Kate Pecora, Field Correspondent, Patients Rising
Myisha Malone King, Patient Advocate
Adam Johnson, Patient Correspondent
The successful patient is one who can get what they need when they need it. We all know insurance slows us down, so why not take matters into your own hands? Our Navigator is an online tool that allows you to search a massive network of health-related resources using your zip code so you get local results. Get proactive and become a more successful patient right now at PatientsRisingConcierge.org
Have a question or comment about the show, or want to suggest a show topic or share your story as a patient correspondent?
Drop us a line: email@example.com
The views and opinions expressed herein are those of the guest(s)/ author(s) and do not reflect the official policy or position of Patients Rising.